Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.25 USD | -6.34% | -11.92% | -26.14% |
Business Summary
Number of employees: 17
Managers
Managers | Title | Age | Since |
---|---|---|---|
Stephen Brady
CEO | Chief Executive Officer | 54 | 19-08-31 |
Nicholas Maestas
DFI | Director of Finance/CFO | 44 | 21-07-11 |
Darrin Bomba
CTO | Chief Tech/Sci/R&D Officer | - | 21-11-30 |
Sam Whiting
CTO | Chief Tech/Sci/R&D Officer | 58 | 20-10-31 |
Comptroller/Controller/Auditor | 36 | 22-05-31 | |
Sharon Sakai
LAW | General Counsel | - | - |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 56 | 21-06-30 | |
Geoffrey Nichol
BRD | Director/Board Member | 69 | 19-11-30 |
Mike Raab Raab
CHM | Chairman | 59 | 20-12-31 |
Ronit Simantov
BRD | Director/Board Member | 59 | 21-08-05 |
Stephen Brady
CEO | Chief Executive Officer | 54 | 19-08-31 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 22,217,265 | 22,203,364 ( 99.94 %) | 0 | 99.94 % |
Company contact information
Tempest Therapeutics, Inc.
2000 Sierra Point Parkway Suite 400
94005, Brisbane
+
http://www.tempesttx.comSector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-26.14% | 72.21M | |
+17.96% | 44.96B | |
+1.17% | 42.65B | |
+48.77% | 41.85B | |
-4.27% | 29.04B | |
+11.42% | 26.08B | |
-21.39% | 19.03B | |
+4.86% | 12.75B | |
+27.29% | 12.06B | |
-3.50% | 11.75B |
- Stock Market
- Equities
- TPST Stock
- Company Tempest Therapeutics, Inc.